Department of Physical Examination, the First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, China.
Department of Physical Examination, Jinzhou Medical University, Jinzhou, Liaoning, China.
Medicine (Baltimore). 2024 May 10;103(19):e37998. doi: 10.1097/MD.0000000000037998.
Hepatocellular carcinoma (HCC) is one of the most common cancers globally, seriously endangering people health. Vitamin D was significantly associated with tumor progression and patients' prognosis. Integrative 10 machine learning algorithms were used to develop a Vitamin D-related signature (VRS) with one training cohort and 3 testing cohorts. The performance of VRS in predicting the immunology response was verified using several predicting approaches. The optimal VRS was constructed by stepCox + superPC algorithm. VRS acted as a risk factor for HCC patients. HCC patients with high-risk score had a poor clinical outcome and the AUCs of 1-, 3-, and 5-year ROC were 0.786, 0.755, and 0.786, respectively. A higher level of CD8 + cytotoxic T cells and B cells was obtained in HCC patients with low-risk score. There is higher PD1&CTLA4 immunophenoscore and TMB score in low-risk score in HCC patients. Lower TIDE score and tumor escape score was found in HCC cases with low-risk score. The IC50 value of camptothecin, docetaxel, crizotinib, dasatinib, and erlotinib was lower in HCC cases with high-risk score. HCC patients with high-risk score had a higher score of cancer-related hallmarks, including angiogenesis, glycolysis, and NOTCH signaling. Our study proposed a novel VRS for HCC, which served as an indicator for predicting clinical outcome and immunotherapy responses in HCC.
肝细胞癌 (HCC) 是全球最常见的癌症之一,严重威胁着人们的健康。维生素 D 与肿瘤进展和患者预后显著相关。我们使用了 10 种整合机器学习算法,通过一个训练队列和 3 个测试队列,开发了一个与维生素 D 相关的特征 (VRS)。我们使用几种预测方法验证了 VRS 预测免疫反应的性能。最优的 VRS 由 stepCox + superPC 算法构建。VRS 是 HCC 患者的一个危险因素。高风险评分的 HCC 患者临床结局较差,1 年、3 年和 5 年 ROC 的 AUC 分别为 0.786、0.755 和 0.786。低风险评分的 HCC 患者中 CD8+细胞毒性 T 细胞和 B 细胞水平较高。低风险评分的 HCC 患者的 PD1&CTLA4 免疫表型评分和 TMB 评分较高。低风险评分的 HCC 病例中 TIDE 评分和肿瘤逃逸评分较低。卡培他滨、多西他赛、克唑替尼、达沙替尼和厄洛替尼的 IC50 值在高风险评分的 HCC 病例中较低。高风险评分的 HCC 患者具有更高的癌症相关特征评分,包括血管生成、糖酵解和 NOTCH 信号。我们的研究提出了一种新的 HCC VRS,可作为预测 HCC 患者临床结局和免疫治疗反应的指标。